Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
AssigneeImmunityBio, Inc.
InventorsJohn H. Lee, Laurent H. Boissel, Hans G. Klingemann
Life of this patent
Estimating the term…
Loading patent…
AssigneeImmunityBio, Inc.
InventorsJohn H. Lee, Laurent H. Boissel, Hans G. Klingemann
Estimating the term…
A recombinant natural killer (NK) cell or T-cell composition is transfected with a nucleic acid encoding i) a homing receptor; ii) an antigen binding protein (ABP) or a chimeric antigen receptor (CAR) that specifically binds a target antigen; iii) an Fc Receptor; and/or iv) a secreted immune modulator selected from a TGFβ inhibitor and/or IL-12, where the recombinant cell is gamma (γ)-irradiated conferring inhibition of cell proliferation with transient activity of the transfected molecules including the secreted immune modulators for up to 72 hours.
A recombinant natural killer (NK)-92 cell transfected with a plasmid expression vector and gamma (γ)-irradiated,
Dependencies are inferred from the claim text.